Drug Profile
Elvucitabine
Alternative Names: ACH-126443; Beta-L-Fd4C; Beta-LFD4C; FD4C-beta-LLatest Information Update: 25 Sep 2021
Price :
$50
*
At a glance
- Originator Yale University
- Developer Achillion Pharmaceuticals
- Class Antivirals; Deoxyribonucleosides; Pyrimidine nucleosides; Small molecules
- Mechanism of Action Nucleoside reverse transcriptase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Suspended Hepatitis B; HIV infections
Most Recent Events
- 28 Jan 2020 Achillion Pharmaceuticals has been acquired by Alexion Pharmaceuticals
- 20 Feb 2014 Suspended - Phase-II for HIV infections (Combination therapy, Treatment-naive) in Puerto Rico (PO)
- 20 Feb 2013 Suspended - Phase-II for Hepatitis B in USA, Canada, Eastern Europe and Central Europe (PO)